Rep. Josh Gottheimer Sells Off Shares of Genmab A/S (NASDAQ:GMAB)

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Genmab A/S (NASDAQ:GMAB). In a filing disclosed on January 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Genmab A/S stock on December 16th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Block (NYSE:SQ) on 12/30/2024.
• Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 12/30/2024.
• Sold $1,001 – $15,000 in shares of Ambev (NYSE:ABEV) on 12/27/2024.
• Sold $1,001 – $15,000 in shares of Grupo Financiero Banorte (OTCMKTS:GBOOY) on 12/27/2024.
• Sold $1,001 – $15,000 in shares of Cadre (NYSE:CDRE) on 12/27/2024.
• Sold $1,001 – $15,000 in shares of Coloplast A/S (OTCMKTS:CLPBY) on 12/27/2024.
• Sold $1,001 – $15,000 in shares of Intuitive Surgical (NASDAQ:ISRG) on 12/23/2024.
• Sold $1,001 – $15,000 in shares of Trane Technologies (NYSE:TT) on 12/23/2024.
• Purchased $1,001 – $15,000 in shares of Walmart (NYSE:WMT) on 12/20/2024.
• Sold $1,001 – $15,000 in shares of NVIDIA (NASDAQ:NVDA) on 12/19/2024.

Genmab A/S Stock Down 6.5 %

GMAB stock opened at $20.23 on Thursday. The stock has a market capitalization of $13.39 billion, a price-to-earnings ratio of 19.64, a price-to-earnings-growth ratio of 0.59 and a beta of 0.97. Genmab A/S has a 52-week low of $19.85 and a 52-week high of $31.88. The stock’s fifty day simple moving average is $21.27 and its 200-day simple moving average is $24.15.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The business had revenue of $816.10 million for the quarter, compared to analysts’ expectations of $838.20 million. During the same quarter last year, the company posted $0.47 earnings per share. As a group, analysts anticipate that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

Institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its stake in shares of Genmab A/S by 4.9% during the second quarter. Bank of New York Mellon Corp now owns 70,171 shares of the company’s stock worth $1,763,000 after purchasing an additional 3,283 shares in the last quarter. Rhumbline Advisers lifted its position in Genmab A/S by 7.1% during the 2nd quarter. Rhumbline Advisers now owns 18,694 shares of the company’s stock worth $470,000 after acquiring an additional 1,236 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in Genmab A/S by 360.8% in the 2nd quarter. Acadian Asset Management LLC now owns 38,010 shares of the company’s stock worth $954,000 after acquiring an additional 29,762 shares during the period. Headlands Technologies LLC grew its position in Genmab A/S by 1,702.8% in the second quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock valued at $129,000 after acquiring an additional 4,853 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. grew its position in Genmab A/S by 26.3% in the second quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company’s stock valued at $5,480,000 after acquiring an additional 45,376 shares in the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on GMAB shares. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. BMO Capital Markets reissued an “outperform” rating and set a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Redburn Atlantic initiated coverage on Genmab A/S in a research report on Tuesday, October 8th. They issued a “buy” rating on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.20.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2025. Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2024 election. Gottheimer was first elected to the House in 2016. Prior to his election, Gottheimer worked for Microsoft, the Federal Communications Commission, and for the administration of President Bill Clinton (D). Click here for more information about Gottheimer’s career. Gottheimer serves on the House Financial Services Committee, where is a member of three subcommittees. For more on Gottheimer’s committee assignments, click here. Gottheimer became a co-chair of the Problem Solvers Caucus in February 2017. Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.